When a harmless procedure causes a life‐threatening problem: a case report of metformin‐associated lactic acidosis following a colonoscopy
Abstract
Metformin is the preferred initial pharmacologic agent for the treatment of adults with type 2 diabetes mellitus. Although considered safe, it carries a potential life‐threatening risk of lactic acidosis. Metformin‐associated lactic acidosis is believed to be a consequence of metformin inhibition of the mitochondrial respiratory chain, and has a mortality ranging between 10–50%. However, its outcome is better than lactic acidosis of other cause with similarly severe acid‐base imbalance.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.